Bruno scheller for the paccocath isr study group l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 16

Bruno Scheller for the Paccocath ISR Study Group PowerPoint PPT Presentation


  • 118 Views
  • Uploaded on
  • Presentation posted in: General

TCT 2007 - Late Breaking Studies and First Report Investigations Wednesday, October 24 2007, Main area PACCOCATH ISR 1 and 2: A Prospective, Randomized Trial of a Paclitaxel-Eluting Balloon in In-Stent Restenosis: 2-Year Results. Bruno Scheller for the Paccocath ISR Study Group.

Download Presentation

Bruno Scheller for the Paccocath ISR Study Group

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Bruno scheller for the paccocath isr study group l.jpg

TCT 2007 - Late Breaking Studies and First Report InvestigationsWednesday, October 24 2007, Main areaPACCOCATH ISR 1 and 2: A Prospective, Randomized Trial of a Paclitaxel-Eluting Balloon in In-Stent Restenosis: 2-Year Results

Bruno Scheller

for the Paccocath ISR Study Group

Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg / Saar, Germany


Slide2 l.jpg

Drug-Eluting Balloon (DEB)

  • Drug-Eluting Stent

  • Slow release

  • Persistent drug exposure

  • ~ 100 - 200 µg dose

  • Polymer

  • Stent mandatory

  • Drug-Eluting Balloon

  • Immediate release

  • Short-lasting exposure

  • ~ 300 - 600 µg dose

  • No polymers

  • Premounted stent optional

Heart 2007, 93: 539-41


Slide3 l.jpg

Paccocath ISR I/II

Efficacy and Safety of Paclitaxel-Coated Balloons

in Coronary In-Stent Restenosis

Homburg/Saar, Freiburg, Charité Mitte Berlin,

Charité Virchow Berlin, Mannheim-Heidelberg

  • Two trials

    • separately randomized

    • double-blind, multicenter

    • identical protocol

    • 108 patients in total

  • Paccocath ISR I

    • 52 patients

  • Paccocath ISR II

    • 56 patients


Slide4 l.jpg

Paccocath ISR I/II

  • Primary endpoint

    • In-segment late lumen loss after 6 months

    • Independent, blinded angiographic core lab

      • U. Dietz, Wiesbaden

  • Secondary endpoints

    • Binary restenosis rate, MACE

  • Statistics

    • p-values adjusted according to Fisher’s method of combining independent tests

  • ASA + clopidogrel

    • 4 weeks in both groups

  • Main inclusion criteria

    • Clinically relevant coronary ISR

    • Diameter stenosis > 70 %

    • Lesion length < 30 mm

    • Vessel diameter 2.5 to 3.5 mm

  • Repeated PTCA of coronary ISR

    • Coated balloon with 3 µg paclitaxel / mm² balloon surface

    • Uncoated balloon of the same type (BMT, Oberpfaffenhofen)


Slide5 l.jpg

Paccocath ISR I/II – Patient Characteristics

p-values adjusted according to Fisher’s method of combining independent tests


Slide6 l.jpg

Paccocath ISR I/II - Lesions

p-values adjusted according to Fisher’s method of combining independent tests


Slide7 l.jpg

Paccocath ISR I/II - Intervention

p-values adjusted according to Fisher’s method of combining independent tests


Slide8 l.jpg

Paccocath ISR I/II

Angiographic measurements at treatment

p-values adjusted according to Fisher’s method of combining independent tests


Slide9 l.jpg

Paccocath ISR I/II

Angiographic measurements at follow-up angiography

p-values adjusted according to Fisher’s method of combining independent tests


Slide10 l.jpg

Paccocath ISR I/II

24 month Clinical follow-up

Intention-to-treat analysis; p-values adjusted according to Fisher’s method of combining independent tests


Slide11 l.jpg

Paccocath ISR I/II - MACE

TLR, MI, acute/subacute closure, stroke, or death

Mantel-Cox log-rank test; p-values adjusted according to Fisher’s method of combining independent tests


Slide12 l.jpg

Paccocath ISR I vs. II


Slide13 l.jpg

Paccocath ISR I vs. II

Late lumen loss in-segment


Slide14 l.jpg

Conclusions

  • First in man trial with a paclitaxel-coated balloon

  • Angiographic and clinical efficacy up to 24 months

  • Safety 24 months

    • no late thrombosis

    • clopidogrel only for one month

  • No coating-related adverse events

  • Inhibition of restenosis by drug-coated balloons does not require stent implantation and sustained drug release at the site of injury.


Slide15 l.jpg

DEB - clinical applications

  • Treatment of ISR

    • Paccocath ISR I/II

    • PEPCAD II

  • Small vessels

    • PEPCD I

  • Bifurcation lesions

    • PEPCAD V

  • DEB with pre-mounted stent

    • PEPCAD III

  • Peripheral artery disease

    • THUNDER

    • PACCOCATH FEM

  • Pediatric cardiology


Slide16 l.jpg

Paccocath ISR Study Group

  • Study centers

    • Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg/Saar (M. Böhm, B. Cremers, M. Kindermann, U. Laufs, T. Müller, B. Scheller, J. Schmidt, S. Siaplaouras; N. Hollinger, B. Werner)

    • Innere Medizin III, Medizinische Universitätsklinik, Freiburg i. Br. (Christoph Hehrlein; A. Becherer)

    • Kardiologie, Campus Virchow-Klinikum, Charité, Berlin (Wolfgang Bocksch, J. Waigand)

    • Kardiologie, Campus Mitte, Charité, Berlin (Wolfgang Rutsch; S. Schroeckh)

    • I. Medizinische Klinik, Universitätsklinikum, Mannheim-Heidelberg (Dariush Haghi, K. Haase, T. Süsselbeck)

  • Angiographic Core Lab

    • Deutsche Klinik für Diagnostik, Wiesbaden (Ulrich Dietz, K. Wilhelmi; Quantitative Coronary Angiography)

  • Pharmaceutical Development

    • Ulrich Speck; Charité, Berlin

  • Devices and Sponsoring

    • Bavaria Medizin Technologie, Oberpfaffenhofen

    • Bayer-Schering Pharma AG, Berlin


  • Login